{"id":51602,"date":"2022-12-06T12:02:33","date_gmt":"2022-12-06T11:02:33","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/simbiosys-highlights-key-advances-for-medical-and-surgical-planning-in-breast-cancer-at-sabcs-2022\/"},"modified":"2022-12-06T12:02:33","modified_gmt":"2022-12-06T11:02:33","slug":"simbiosys-highlights-key-advances-for-medical-and-surgical-planning-in-breast-cancer-at-sabcs-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/simbiosys-highlights-key-advances-for-medical-and-surgical-planning-in-breast-cancer-at-sabcs-2022\/","title":{"rendered":"SimBioSys\u00ae highlights key advances for medical and surgical planning in breast cancer at SABCS 2022"},"content":{"rendered":"<div>\n<p class=\"bwalignc\">\n<i>The company\u2019s 4D tumor modeling<\/i>\u2122 <i>technology is featured in six poster presentations showing the breath of its utility across surgical and medical oncology.<\/i>\n<\/p>\n<p>CHICAGO&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/hashtag\/4Dtumormodeling?src=hash\" target=\"_blank\" rel=\"noopener\">#4Dtumormodeling<\/a>&#8211;SimBioSys, the precision oncology company behind the 4D Tumor Modeling\u2122<sup> <\/sup>technology, is presenting their latest breast cancer research and introducing new technology applications at the 2022 San Antonio Breast Cancer Symposium (SABCS). SimBioSys will also exhibit at booth 823.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20221206005295\/en\/1655685\/5\/SimBioSys_Logo_Blue.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20221206005295\/en\/1655685\/21\/SimBioSys_Logo_Blue.jpg\"><\/a><\/p>\n<p>\nThe studies covering six separate poster presentations at SABCS are based on data from both internal and external validation studies of SimBioSys\u2019 proprietary platform. The results include collaborations with top cancer research institutions, multi-institutional analysis, enhanced visualization, and volumetric prediction capabilities to aid surgical planning as well as novel biomarkers.\n<\/p>\n<p>\n\u201cOur presentations at SABCS demonstrate our multidisciplinary approach and the clinical utility of our 4D modeling technology. We are incredibly proud of the research and clinical collaborations with key leaders in breast cancer and the impact our technology can have in breast cancer care,\u201d said Dr. Anuja Antony, Chief Medical Officer of SimBioSys.\n<\/p>\n<p>\nThe company will be presenting abstracts validating their visualization and prediction technology which offers pCR prediction and recurrence free survival, surgical planning and biomarker development. Details about the presentations can be found below:\n<\/p>\n<p>\n<b>P1-04-07: pCR Score: a novel prognostic method to estimate the predictive probability of pCR in early-stage breast cancer patients<\/b>\n<\/p>\n<p>\nPeterson J, et. al.\n<\/p>\n<p>\nWhen: Tuesday December 6, 2022\n<\/p>\n<p>\nWhere: Poster session 1 \u2013 Hall 1\n<\/p>\n<p>\nResearch conducted with: Berry Consultants, LLC; University of Chicago; Northwest Community Healthcare; Baylor Scott &amp; White Health; University of Cincinnati; University of North Carolina, Lineberger Comprehensive Cancer Center; Springfield Clinic; University of Arizona Cancer Center.\n<\/p>\n<p>\n<b>P1-04-08: Independent validation of a novel, non-invasive approach to predict pathologic complete response (pCR) in a blinded, prospectively-run single center trial<\/b>\n<\/p>\n<p>\nKuzmiak C, et. al.\n<\/p>\n<p>\nWhen: Tuesday December 6, 2022\n<\/p>\n<p>\nWhere: Poster session 1 \u2013 Hall 1\n<\/p>\n<p>\nResearch conducted with: University of North Carolina, Lineberger Comprehensive Cancer Center\n<\/p>\n<p>\n<b>P4-02-19: Development of a novel imaging biomarker to ascertain responsiveness to immunotherapy<\/b>\n<\/p>\n<p>\nCook D, et. al.\n<\/p>\n<p>\nWhen: Thursday December 8, 2022\n<\/p>\n<p>\nWhere: Poster session 2 \u2013 Hall 1\n<\/p>\n<p>\n<b>P4-02-24: A 3D visualization and prediction device for breast cancer surgeons and their patients<\/b>\n<\/p>\n<p>\nParker A, et. al.\n<\/p>\n<p>\nWhen: Thursday December 8, 2022\n<\/p>\n<p>\nWhere: Poster session 2 \u2013 Hall 1\n<\/p>\n<p>\n<b>P4-02-29: A 3D visualization method for breast cancer surgeons and patients<\/b>\n<\/p>\n<p>\nParker A, et. al.\n<\/p>\n<p>\nWhen: Thursday December 8, 2022\n<\/p>\n<p>\nWhere: Poster session 2 \u2013 Hall 1\n<\/p>\n<p>\n<b>P6-01-36: Validation of prognostic platform to further refine identification high risk patients indicated for chemotherapy free treatment in early-stage breast cancer<\/b>\n<\/p>\n<p>\nPeterson J, et. al.\n<\/p>\n<p>\nWhen: Friday December 9, 2022\n<\/p>\n<p>\nWhere: Poster session 2 \u2013 Hall 1\n<\/p>\n<p>\nResearch conducted with: NorthShore University Health System.\n<\/p>\n<p>\n<b><span class=\"bwuline\">About SimBioSys:<\/span><\/b>\n<\/p>\n<p>\nSimBioSys is a technology company deploying a combination of artificial intelligence and biophysics-based simulations to improve our understanding of cancer. By virtualizing cancer, SimBioSys aims to empower clinicians and patients with a comprehensive understanding of the disease and treatment options.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nDorys Lopez<br \/>\n<br \/>SimBioSys<br \/>\n<br \/><a target=\"_blank\" href=\"ma&#105;&#108;&#x74;&#x6f;&#x3a;&#x6d;ed&#105;&#97;&#x40;&#x73;&#x69;&#x6d;bi&#111;&#115;&#121;&#x73;&#x2e;&#x63;&#x6f;m\" rel=\"nofollow noopener\" shape=\"rect\">&#109;&#x65;&#100;&#x69;a&#x40;s&#105;&#x6d;&#98;&#x69;o&#x73;y&#115;&#x2e;&#99;&#x6f;m<\/a><br \/>+1-872-365-3112\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>The company\u2019s 4D tumor modeling\u2122 technology is featured in six poster presentations showing the breath of its utility across surgical and medical oncology. CHICAGO&#8211;(BUSINESS WIRE)&#8211;#4Dtumormodeling&#8211;SimBioSys, the precision oncology company behind the 4D Tumor Modeling\u2122 technology, is presenting their latest breast cancer research and introducing new technology applications at the 2022 San Antonio Breast Cancer Symposium &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/simbiosys-highlights-key-advances-for-medical-and-surgical-planning-in-breast-cancer-at-sabcs-2022\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["entry","post","publish","author-business","post-51602","format-standard","category-industry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SimBioSys\u00ae highlights key advances for medical and surgical planning in breast cancer at SABCS 2022 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/simbiosys-highlights-key-advances-for-medical-and-surgical-planning-in-breast-cancer-at-sabcs-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SimBioSys\u00ae highlights key advances for medical and surgical planning in breast cancer at SABCS 2022 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"The company\u2019s 4D tumor modeling\u2122 technology is featured in six poster presentations showing the breath of its utility across surgical and medical oncology. CHICAGO&#8211;(BUSINESS WIRE)&#8211;#4Dtumormodeling&#8211;SimBioSys, the precision oncology company behind the 4D Tumor Modeling\u2122 technology, is presenting their latest breast cancer research and introducing new technology applications at the 2022 San Antonio Breast Cancer Symposium ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/simbiosys-highlights-key-advances-for-medical-and-surgical-planning-in-breast-cancer-at-sabcs-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-06T11:02:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221206005295\/en\/1655685\/21\/SimBioSys_Logo_Blue.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/simbiosys-highlights-key-advances-for-medical-and-surgical-planning-in-breast-cancer-at-sabcs-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/simbiosys-highlights-key-advances-for-medical-and-surgical-planning-in-breast-cancer-at-sabcs-2022\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"SimBioSys\u00ae highlights key advances for medical and surgical planning in breast cancer at SABCS 2022\",\"datePublished\":\"2022-12-06T11:02:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/simbiosys-highlights-key-advances-for-medical-and-surgical-planning-in-breast-cancer-at-sabcs-2022\\\/\"},\"wordCount\":496,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/simbiosys-highlights-key-advances-for-medical-and-surgical-planning-in-breast-cancer-at-sabcs-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221206005295\\\/en\\\/1655685\\\/21\\\/SimBioSys_Logo_Blue.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/simbiosys-highlights-key-advances-for-medical-and-surgical-planning-in-breast-cancer-at-sabcs-2022\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/simbiosys-highlights-key-advances-for-medical-and-surgical-planning-in-breast-cancer-at-sabcs-2022\\\/\",\"name\":\"SimBioSys\u00ae highlights key advances for medical and surgical planning in breast cancer at SABCS 2022 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/simbiosys-highlights-key-advances-for-medical-and-surgical-planning-in-breast-cancer-at-sabcs-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/simbiosys-highlights-key-advances-for-medical-and-surgical-planning-in-breast-cancer-at-sabcs-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221206005295\\\/en\\\/1655685\\\/21\\\/SimBioSys_Logo_Blue.jpg\",\"datePublished\":\"2022-12-06T11:02:33+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/simbiosys-highlights-key-advances-for-medical-and-surgical-planning-in-breast-cancer-at-sabcs-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/simbiosys-highlights-key-advances-for-medical-and-surgical-planning-in-breast-cancer-at-sabcs-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/simbiosys-highlights-key-advances-for-medical-and-surgical-planning-in-breast-cancer-at-sabcs-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221206005295\\\/en\\\/1655685\\\/21\\\/SimBioSys_Logo_Blue.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221206005295\\\/en\\\/1655685\\\/21\\\/SimBioSys_Logo_Blue.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/simbiosys-highlights-key-advances-for-medical-and-surgical-planning-in-breast-cancer-at-sabcs-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SimBioSys\u00ae highlights key advances for medical and surgical planning in breast cancer at SABCS 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SimBioSys\u00ae highlights key advances for medical and surgical planning in breast cancer at SABCS 2022 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/simbiosys-highlights-key-advances-for-medical-and-surgical-planning-in-breast-cancer-at-sabcs-2022\/","og_locale":"en_US","og_type":"article","og_title":"SimBioSys\u00ae highlights key advances for medical and surgical planning in breast cancer at SABCS 2022 - Pharma Trend","og_description":"The company\u2019s 4D tumor modeling\u2122 technology is featured in six poster presentations showing the breath of its utility across surgical and medical oncology. CHICAGO&#8211;(BUSINESS WIRE)&#8211;#4Dtumormodeling&#8211;SimBioSys, the precision oncology company behind the 4D Tumor Modeling\u2122 technology, is presenting their latest breast cancer research and introducing new technology applications at the 2022 San Antonio Breast Cancer Symposium ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/simbiosys-highlights-key-advances-for-medical-and-surgical-planning-in-breast-cancer-at-sabcs-2022\/","og_site_name":"Pharma Trend","article_published_time":"2022-12-06T11:02:33+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221206005295\/en\/1655685\/21\/SimBioSys_Logo_Blue.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/simbiosys-highlights-key-advances-for-medical-and-surgical-planning-in-breast-cancer-at-sabcs-2022\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/simbiosys-highlights-key-advances-for-medical-and-surgical-planning-in-breast-cancer-at-sabcs-2022\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"SimBioSys\u00ae highlights key advances for medical and surgical planning in breast cancer at SABCS 2022","datePublished":"2022-12-06T11:02:33+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/simbiosys-highlights-key-advances-for-medical-and-surgical-planning-in-breast-cancer-at-sabcs-2022\/"},"wordCount":496,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/simbiosys-highlights-key-advances-for-medical-and-surgical-planning-in-breast-cancer-at-sabcs-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221206005295\/en\/1655685\/21\/SimBioSys_Logo_Blue.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/simbiosys-highlights-key-advances-for-medical-and-surgical-planning-in-breast-cancer-at-sabcs-2022\/","url":"https:\/\/pharma-trend.com\/en\/simbiosys-highlights-key-advances-for-medical-and-surgical-planning-in-breast-cancer-at-sabcs-2022\/","name":"SimBioSys\u00ae highlights key advances for medical and surgical planning in breast cancer at SABCS 2022 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/simbiosys-highlights-key-advances-for-medical-and-surgical-planning-in-breast-cancer-at-sabcs-2022\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/simbiosys-highlights-key-advances-for-medical-and-surgical-planning-in-breast-cancer-at-sabcs-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221206005295\/en\/1655685\/21\/SimBioSys_Logo_Blue.jpg","datePublished":"2022-12-06T11:02:33+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/simbiosys-highlights-key-advances-for-medical-and-surgical-planning-in-breast-cancer-at-sabcs-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/simbiosys-highlights-key-advances-for-medical-and-surgical-planning-in-breast-cancer-at-sabcs-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/simbiosys-highlights-key-advances-for-medical-and-surgical-planning-in-breast-cancer-at-sabcs-2022\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221206005295\/en\/1655685\/21\/SimBioSys_Logo_Blue.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221206005295\/en\/1655685\/21\/SimBioSys_Logo_Blue.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/simbiosys-highlights-key-advances-for-medical-and-surgical-planning-in-breast-cancer-at-sabcs-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"SimBioSys\u00ae highlights key advances for medical and surgical planning in breast cancer at SABCS 2022"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51602","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=51602"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51602\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=51602"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=51602"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=51602"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}